First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Moderna COVID-19 vaccine patent dispute headed to court...

Newsdeck

patent dispute

Moderna COVID-19 vaccine patent dispute headed to court, U.S. NIH head says

A box of the Moderna Covid-19 vaccine vials at a drive-thru vaccination site at the Meigs County fairgrounds in Pomeroy, Ohio, U.S., on Thursday, March 18, 2021. President Joe Biden is poised to meet his goal of delivering 100 million Covid-19 vaccine shots in his first 100 days in office as soon as Thursday, reaching the milestone more than a month ahead of time. Photographer: Stephen Zenner/Bloomberg
By Reuters
11 Nov 2021 0

CHICAGO, Nov 10 (Reuters) - U.S. National Institutes of Health scientists played "a major role" in developing Moderna Inc's COVID-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH Director Dr. Francis Collins told Reuters on Wednesday.

In a story first reported by the New York Times on Tuesday, Moderna excluded three NIH scientists as co-inventors of a central patent for the company’s multibillion-dollar COVID-19 vaccine in its application filed in July.

“I think Moderna has made a serious mistake here in not providing the kind of co-inventorship credit to people who played a major role in the development of the vaccine that they’re now making a fair amount of money off of,” Collins said in an interview ahead of the Reuters Total Health conference, which will run virtually from Nov. 15-18.

Moderna expects 2021 sales of $15 billion to $18 billion from the COVID-19 vaccine – its first and only commercial product – and up to $22 billion next year.

In a statement emailed to Reuters, Moderna acknowledged that scientists at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) played a “substantial role” in developing Moderna’s messenger RNA (mRNA) vaccine, but the company said it disagrees with the agency’s patent claims.

Collins said the NIH has been trying to resolve the patent conflict with Moderna amicably for some time and has failed.

“But we are not done. Clearly this is something that legal authorities are going to have to figure out,” he said.

NIH has asserted that three of its scientists – Dr. John Mascola, Dr. Barney Graham and Dr. Kizzmekia Corbett – helped design the genetic sequence used in Moderna’s vaccine and should be named on the patent application. Graham has since retired and Corbett is now working at Harvard.

“It’s not a good idea to file a patent when you leave out important inventors, and so this is going to get sorted as people look harder at this,” Collins told Reuters.

“I did not expect that to be the outcome from what had been a very friendly, collaborative effort between scientists at NIH and Moderna over many years.”

In its statement, Moderna said, “We do not agree that NIAID scientists co-invented claims to the mRNA-1273 sequence itself. Only Moderna’s scientists came up with the sequence for the mRNA used in our vaccine.”

Moderna said the company has acknowledged NIH scientists in other patent applications, such as those related to dosing. But for the core patent, Moderna is only required to list Moderna scientists as inventors of the sequence under the strict rules of U.S. patent law, it said.

“We are grateful for our collaboration with NIH scientists, value their contributions, and remain focused on working together to help patients,” the company added.

By Julie Steenhuysen.

(Reporting by Julie Steenhuysen Editing by Bill Berkrot)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted